Anteo Diagnostics Investor Presentation May 2015

1. Nanotechnology for
Improvements in
Healthcare,
Energy & Beyond
Geoff Cumming, CEO (ASX:ADO)

2. 2
Forward Looking Statement
Refer to the Company's website for further information. The views expressed in this presentation contain
information derived from publicly available sources that have not been independently verified. No representation or
warranty is made as to the accuracy, completeness or reliability of the information.
Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions
which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are
subject to risks, uncertainties and other factors, many of which are outside Anteo the presentation is to
provide an update of the business of Anteo Diagnostics (ASX:ADO).
These slides have been prepared as a presentation aid only and the information they contain may require further
explanation and/or clarification. Accordingly, these slides and the information they contain should be read in
conjunction with past and future announcements made by Anteo and should not be relied upon as an independent
source of information. Please contact Anteo with any questions.
Important factors that could cause actual results to duffer materially from assumptions or expectations expressed
or implied in this presentation include known and unknown risks. Because actual results could differ materially to
assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged
to view all forward looking statements contained in this presentation with caution.
This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing
in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in
any jurisdiction.

3. What is Nanotechnology?
3
o 1/100,000th of the diameter of a hair
o Nanotechnology is manipulation of
matter at the molecular scale
o Inspired by nature, nanoscale
technology is a new field of chemistry
that:
o Saves the use of raw
materials
o Saves the use of energy and
water
o Reduces greenhouse gases
and hazardous waste
o Nanoglue: Anteo’s core technology
operates at the molecular scale

4. Anteo: Who We Are
4
Inside One of Anteo ‘s State-of-the-Art Labs
o Our patented Nanoglue binds materials together
o Our primary focus is applications of our Nanoglue in the In Vitro
Diagnostic (IVD) and Life Science (LS) markets
o Improves outcomes with biological and synthetic materials
o The versatility and need for our Nanoglue technology has created
3 secondary areas of business:
o Bioseparations
o Medical Devices
o Batteries

5. Anteo: What We Do
5
o Bind biological molecules to synthetic surfaces
o Increase their functionality
o Increase stability and reproducibility
o Simplify procedures
o Reduce handling time and costs
o Stabilise material interactions to increase their functionality/capacity
Anteo’s patented nanotechnology is providing powerful tools that
are
transforming the way scientists work

6. 6
Business Area 1: The IVD Market
o The global in vitro diagnostics (IVD) market is growing robustly,
despite economic and industry challenges
o Double the rate of the global pharmaceutical industry
o The market will remain buoyant due to the recent success of cost-
saving companion diagnostics tests and personalised medicine
o $47.27 billion in revenue in 2013
o $62.63 billion estimated revenue by 2017 ($15bn accessible)
Source: Frost & Sullivan’s Analysis of the Global In Vitro Diagnostics Market 2014

7. 7
How Does Our Nanotechnology Work in IVD/LS?
o Mix&Go™ - the name of our healthcare Nanoglue family
o Utilises coordination chemistry (rather than covalent chemistry or
passive binding) for gentle and secure multipoint binding of
biomolecules to synthetic surfaces
o Ease of use, increased antibody functionality and decreased
background interference
o Greater sensitivity of tests, reducing costs to manufacture and
supporting the earlier detection of disease

8. 8
IVD/LS Market Revenue Generation: Process
The Stages of a Revenue Generating Partnership
o Sell a ‘teaser’ product
o Anteo assess each partnership and the support that is required -
charges fees proportional to time and challenge of the task
o Amount of revenue generated pre launch: $20,000 - $500,000+
per project
o At market launch stage, Anteo begins to generate royalty or supply
revenues

9. 9
Adoption of Mix&Go In The IVD/LS Markets
o Licensing - (Merck KGaA, Affymetrix, Bangs Laboratories)
o Co-development of products through partnerships (BBI, IMRA,
POC1 plus a number of global life science and veterinary companies
worldwide)
o Product Sales - Mix&Go Reagents, Coupling and Activation Kits are
being sold and used globally
o Distribution - Veritas Corporation recently signed an agreement
for exclusive distribution rights in Japan

10. 10
Business Area 2: Bioseparations
o A variation of use for Mix&Go Nanoglue family
o $6 billion market by 2018*
o Applications
o Blood purification - Blood banks and sample pre-treatment for
diagnostic testing (patent filed)
o Protein purification
o Drug manufacturing – Therapeutic antibodies
o Current position – Undertaking a collaborative project with a
global life science company that is extending an existing Anteo
product to deliver a proprietary Bioseparations product
*Source www.biopharma-reporter.com

11. 11
Business Area 3: Medical Devices
o Using variations of our Nanoglue
o Attaching biomolecules to synthetic surfaces
o $52 billion implantable medical device market*
o Partnership with Cook Medical Australia
o Partnership with University of Queensland
exploring In Vivo usage
o Expecting to file patents in the near future
*Source: Freedonia Group

12. 12
Business Area 4: Batteries
o A variation of our Nanoglue
o Stabilisation of existing and new
materials
o Li-Ion market estimated at $30
billion pa, increasing to $50 billion
pa in 2018*
*Source: Avicenne, Roland Berger, October 2012; Takeshita 2010
o Key Sectors: Automotive, mobile phones, tablets, laptops, digital
cameras, power tools, toys, other portable electronic devices, and
defense
o Key Drivers: Cost, size, weight, power, capacity, charge rate
o Market Situation: Continuing demand for higher energies with
reduced cost/weight/size

13. 13
Anteo Battery vs Conventional Battery
0
1
2
3
4
5
6
7
8
ANTEO Conventional Graphite Li-
ion batery
Relative Capacity
0
1
2
3
4
5
6
7
ANTEO Conventional Graphite Li-
ion batery
Relative Charge/Discharge
Rate

14. 14
Batteries Developed Using Anteo’s Nanotechnology
Anteo nanotechnology can:
o Increase the capacity of batteries
 Gives lighter and smaller batteries
o Improve the efficiency of charge/discharge
 Increased runtime per charge
o Batteries will charge faster
 Shorter waiting time to charge
o More cycles per battery
 Increased battery life

15. 15
Anteo: Drop In Technology For Manufacturing Batteries
Drop in Anteo
technology at this
stage of the battery
manufacturing
process

16. 16
Vast Potential of Anteo’s Nanotechnology

17. 17
Anteo Board of Directors
Mark Bouris
Non-Executive
Chairman
Geoff Cumming
CEO, Executive
Director
Richard Martin
CFO, Executive
Director
Sandra (Sam)
Andersen
Non-Executive
Director
John Hurrell
Non-Executive
Director
Joe Maeji
Chief
Scientific
Officer
Charlie
Huang
Head of New
Technologies
Josh Soldo
VP Scientific
Affairs
Rachel de las
Heras
Head of
Commercial
Development
Shaun Cooper
Head of
Production
Tina
Baumgartner
VP Business
Development
Management Team

18. 18
Group Snapshot
o Anteo is actively generating revenue through licensing and co-
development of products in the in vitro diagnostics space
o Funding may be required for battery developments and a potential
acquisition
o Current funds enable Anteo to continue core business for 2 years in
absence of additional revenue
Major Shareholders
First Cape Mgt Pty Ltd 13.3%
Nimrod Finance Ltd 2.4%
Dr Geoff Cumming 2.1%
Corporate
ASX ADO
Cash $5.7M
Market Cap. $79M
Av Daily Volume (30 d) 1,413,606
52 week high/low $0.24/$0.08
Shares on issue 844.8M
Top 20 29%
Directors/Staff 16%

19. 19
Geoff Cumming
CEO, Anteo Diagnostics
geoff.cumming@anteodx.com
anteodx.com
Follow @anteodx